\BOOKMARK [0][-]{chapter.1}{Review of computational drug repositioning approaches}{}% 1
\BOOKMARK [1][-]{section.1.1}{Relevance of drug repositioning}{chapter.1}% 2
\BOOKMARK [2][-]{subsection.1.1.1}{Opportunities for finding new indications}{section.1.1}% 3
\BOOKMARK [2][-]{subsection.1.1.2}{Drug repositioning faces legal and scientific challenges}{section.1.1}% 4
\BOOKMARK [1][-]{section.1.2}{Drug repositioning and indication discovery: Success stories}{chapter.1}% 5
\BOOKMARK [2][-]{subsection.1.2.1}{Sildenafil: Repositioning from clinical side-effects}{section.1.2}% 6
\BOOKMARK [2][-]{subsection.1.2.2}{Thalidomide: Repositioning a hazardous drug}{section.1.2}% 7
\BOOKMARK [2][-]{subsection.1.2.3}{Raloxifene: Expanding the application line}{section.1.2}% 8
\BOOKMARK [1][-]{section.1.3}{Computational approaches towards drug repositioning}{chapter.1}% 9
\BOOKMARK [2][-]{subsection.1.3.1}{Chemical structure-based approaches}{section.1.3}% 10
\BOOKMARK [2][-]{subsection.1.3.2}{Gene expression and functional genomics-based approaches}{section.1.3}% 11
\BOOKMARK [2][-]{subsection.1.3.3}{Protein structure and molecular docking-based approaches}{section.1.3}% 12
\BOOKMARK [2][-]{subsection.1.3.4}{Phenotype and side-effect-based approaches}{section.1.3}% 13
\BOOKMARK [2][-]{subsection.1.3.5}{Genetic variation-based approaches}{section.1.3}% 14
\BOOKMARK [2][-]{subsection.1.3.6}{Disease network-based approaches}{section.1.3}% 15
\BOOKMARK [2][-]{subsection.1.3.7}{Machine learning and concepts combination approaches}{section.1.3}% 16
\BOOKMARK [2][-]{subsection.1.3.8}{Summary}{section.1.3}% 17
\BOOKMARK [1][-]{section.1.4}{Thesis: Biological process and molecular function for drug repositioning}{chapter.1}% 18
\BOOKMARK [2][-]{subsection.1.4.1}{Rationale}{section.1.4}% 19
\BOOKMARK [2][-]{subsection.1.4.2}{Towards the specification, implementation and analysis}{section.1.4}% 20
\BOOKMARK [3][-]{subsubsection.1.4.2.1}{Chapter 2 - Description logics and biomedical knowledge \(Specification\)}{subsection.1.4.2}% 21
\BOOKMARK [3][-]{subsubsection.1.4.2.2}{Chapter 3 - The Functional Therapeutic Chemical Classification System \(Implementation\)}{subsection.1.4.2}% 22
\BOOKMARK [3][-]{subsubsection.1.4.2.3}{Chapter 4 - Systematic drug repositioning analysis}{subsection.1.4.2}% 23
\BOOKMARK [3][-]{subsubsection.1.4.2.4}{Chapter 5 - Outlook}{subsection.1.4.2}% 24
\BOOKMARK [0][-]{chapter.2}{Description logics and biomedical knowledge \(Specification\)}{}% 25
\BOOKMARK [1][-]{section.2.1}{Introduction}{chapter.2}% 26
\BOOKMARK [1][-]{section.2.2}{Biomedical knowledge}{chapter.2}% 27
\BOOKMARK [2][-]{subsection.2.2.1}{Formalisation in biomedical sciences}{section.2.2}% 28
\BOOKMARK [3][-]{subsubsection.2.2.1.1}{Formalism varies among natural sciences}{subsection.2.2.1}% 29
\BOOKMARK [3][-]{subsubsection.2.2.1.2}{Organisms as complex machines}{subsection.2.2.1}% 30
\BOOKMARK [2][-]{subsection.2.2.2}{Requirements for biomedical knowledge formalisation}{section.2.2}% 31
\BOOKMARK [1][-]{section.2.3}{Description logics for biomedical knowledge}{chapter.2}% 32
\BOOKMARK [2][-]{subsection.2.3.1}{Problem addressed}{section.2.3}% 33
\BOOKMARK [2][-]{subsection.2.3.2}{Expressivity and complexity}{section.2.3}% 34
\BOOKMARK [0][-]{chapter*.18}{Bibliography}{}% 35
\BOOKMARK [0][-]{appendix.A}{Extra Information}{}% 36
